Melatonin, angiotensin 1-7, and cannabidiol in refractory autoimmune disease: clinical case series
Academia Neuroscience and Brain Research · 05.06.2026 · 2 (2)
DOI: 10.20935/acadneurosci8343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academia Neuroscience and Brain Research, online erschienen am 05.06.2026. Verfasst von Paolo Lissoni und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Introduction
Dysregulation of the TH17/T regulatory (Treg) axis represents a frequently implicated pathway that may contribute to immune imbalance in selected autoimmune diseases, and experimental and clinical evidence suggests that several neuroendocrine systems—including melatonin, the endocannabinoid system, and the ACE2/angiotensin 1-7 axis—inhibit interleukin 17 (IL-17) signaling and physiologically modulate immune homeostasis. Materials and methods: This retrospective, observational case series evaluated 70 consecutive patients with refractory autoimmune diseases who were nonresponsive to or declined conventional immunosuppressive therapies. Patients received an integrative neuroendocrine regimen consisting of oral melatonin (10–50 mg nightly), gastro-protected angiotensin 1-7 (0.5 mg twice daily), and cannabidiol (20 mg twice daily). Outcomes included changes in disease-specific autoantibody titers (anti-thyroglobulin antibodies and antinuclear antibodies), lymphocyte-to-monocyte ratio (LMR) as an exploratory biomarker of systemic inflammation, and clinical or radiological disease stability, particularly in multiple sclerosis.
Results
After 3 months, patients with Hashimoto’s thyroiditis showed a significant reduction in anti-thyroglobulin antibody levels (−49%), while patients with other systemic autoimmune diseases exhibited a significant decline in antinuclear antibody titers (−60%). In the multiple sclerosis subgroup, 62% of patients achieved radiological disease stabilization, with a median follow-up of 46 months. Abnormally low baseline LMR values were normalized in 67% of patients experiencing disease flares at enrollment. The regimen was well tolerated, and no clinically significant adverse events requiring treatment discontinuation were observed.
Conclusions
In this heterogeneous cohort of patients with refractory autoimmune diseases, modulation of the neuroendocrine immune axis using melatonin, angiotensin 1-7, and cannabidiol was feasible, well tolerated, and associated with favorable serological and clinical trends. Given the retrospective, non-controlled design, these findings should be interpreted as hypothesis-generating. Controlled, randomized trials incorporating standardized immunological endpoints are warranted to validate the therapeutic potential of this integrative neuroimmune approach.
Zitieren
APA
Lissoni, P., Messina, G., Monzon, A., Tassoni, S., Sassola, A., Fede, G. D., Silva, A. C. S. E., & Cardinali, D. P. (2026). Melatonin, angiotensin 1-7, and cannabidiol in refractory autoimmune disease: clinical case series. Academia Neuroscience and Brain Research, 2(2). https://doi.org/10.20935/acadneurosci8343
Vancouver
Lissoni P, Messina G, Monzon A, Tassoni S, Sassola A, Fede GD, et al. Melatonin, angiotensin 1-7, and cannabidiol in refractory autoimmune disease: clinical case series. Academia Neuroscience and Brain Research. 2026;2(2). doi:10.20935/acadneurosci8343
BibTeX
@article{Lissoni2026,
author = {Lissoni, Paolo and Messina, Giusy and Monzon, Alejandra and Tassoni, Simonetta and Sassola, Andrea and Fede, Giuseppe Di and Silva, Ana Cristina Simões e and Cardinali, Daniel Pedro},
title = {Melatonin, angiotensin 1-7, and cannabidiol in refractory autoimmune disease: clinical case series},
journal = {Academia Neuroscience and Brain Research},
year = {2026},
volume = {2},
number = {2},
doi = {10.20935/acadneurosci8343}
}
EUVIMED